Abstract
Pancreatic cancer is one of the most aggressive and intractable human malignant tumors and a leading cause of cancer-related death across the world, with incidence equaling mortality. Because of the extremely high malignance, this disease is usually diagnosed at its advanced stage and recurs even after surgical excision. Pancreatic adenocarcinoma is generally thought to arise from pathological changes of pancreatic duct, and the pancreatic ductal adenocarcinoma accounts for more than 90 % of malignant neoplasms of the pancreas. To date, scientists have revealed several risk factors for pancreatic cancer, including smoking, family history, and aging. However, the underlying molecular mechanism remains unclear. Meanwhile, more mutations of DNA damage response factors have been identified in familial pancreatic cancers, implying a potential link between DNA damage and pancreatic cancer. DNA damage is a recurring phenomenon in our bodies which could be induced by exogenous agents and endogenous metabolism. Accumulated DNA lesions cause genomic instability which eventually results in tumorigenesis. In this study, we showed obvious DNA damages existed in human pancreatic cancer, which activated DNA damage response and the DNA repair pathway including ataxia-telangiectasia mutated, DNA-PK, CHK1, and CHK2. The persistent DNA damage in pancreatic tissue may be the source for its tumorigenesis.
References
Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15(17):2177–2196
Bardeesy N, DePinho RA (2002) Pancreatic cancer biology and genetics. Nat Rev Cancer 2(12):897–909
Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8(3):180–192
Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319):1109–1113
Chen L, Trujillo K, Sung P, Tomkinson AE (2000) Interactions of the DNA ligase IV-XRCC4 complex with DNA ends and the DNA-dependent protein kinase. J Biol Chem 275(34):26196–26205
Chiu CC, Li CH, Ung MW, Fuh TS, Chen WL, Fang K (2005) Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells. Cancer Lett 223(2):249–258
Ciccia A, Elledge SJ (2010) The DNA damage response: making it safe to play with knives. Mol Cell 40(2):179–204
Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, Galban CJ, Rakshit S, Flannagan KS, Adsay NV, Pasca di Magliano M (2012) Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 122(2):639–653
Cortez D, Wang Y, Qin J, Elledge SJ (1999) Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286(5442):1162–1166
Eckel F, Schneider G, Schmid RM (2006) Pancreatic cancer: a review of recent advances. Expert Opin Investig Drugs 15(11):1395–1410
Falck J, Coates J, Jackson SP (2005) Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 434(7033):605–611
Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP (2005) Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 41(15):2213–2236
Ghosal G, Chen J (2013) DNA damage tolerance: a double-edged sword guarding the genome. Transl Cancer Res 2(3):107–129
Hirose Y, Berger MS, Pieper RO (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61(5):1957–1963
Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461(7267):1071–1078
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics. CA Cancer J Clin 56(2):106–130
Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324(5924):217
Kadlubar FF, Anderson KE, Haussermann S, Lang NP, Barone GW, Thompson PA, MacLeod SL, Chou MW, Mikhailova M, Plastaras J, Marnett LJ, Nair J, Velic I, Bartsch H (1998) Comparison of DNA adduct levels associated with oxidative stress in human pancreas. Mutat Res 405(2):125–133
Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432(7015):316–323
Komuro Y, Watanabe T, Hosoi Y, Matsumoto Y, Nakagawa K, Suzuki N, Nagawa H (2005) Prognostic significance of Ku70 protein expression in patients with advanced colorectal cancer. Hepatogastroenterology 52(64):995–998
Li M, Yu X (2013) Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell 23(5):693–704
Li D, Firozi PF, Zhang W, Shen J, DiGiovanni J, Lau S, Evans D, Friess H, Hassan M, Abbruzzese JL (2002) DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. Mutat Res 513(1–2):37–48
Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363(9414):1049–1057
Li M, Lu LY, Yang CY, Wang S, Yu X (2013) The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response. Genes Dev 27(16):1752–1768
Lord CJ, Ashworth A (2012) The DNA damage response and cancer therapy. Nature 481(7381):287–294
Ma J, Jemal A (2013) The rise and fall of cancer mortality in the USA: why does pancreatic cancer not follow the trend? Future Oncol 9(7):917–919
Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP, Elledge SJ (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316(5828):1160–1166
Mohammed A, Janakiram NB, Lightfoot S, Gali H, Vibhudutta A, Rao CV (2012) Early detection and prevention of pancreatic cancer: use of genetically engineered mouse models and advanced imaging technologies. Curr Med Chem 19(22):3701–3713
Morrison C, Sonoda E, Takao N, Shinohara A, Yamamoto K, Takeda S (2000) The controlling role of ATM in homologous recombinational repair of DNA damage. EMBO J 19(3):463–471
Nagathihalli NS, Nagaraju G (2011) RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. Biochim Biophys Acta 1816(2):209–218
Ozcelik H, Schmocker B, Di Nicola N, Shi XH, Langer B, Moore M, Taylor BR, Narod SA, Darlington G, Andrulis IL, Gallinger S, Redston M (1997) Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 16(1):17–18
Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BA, Venkitaraman AR (1998) Involvement of Brca2 in DNA repair. Mol Cell 1(3):347–357
Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM (2000) A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 10(15):886–895
Polo SE, Jackson SP (2011) Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev 25(5):409–433
Reinhardt HC, Yaffe MB (2009) Kinases that control the cell cycle in response to DNA damage: chk1, Chk2, and MK2. Curr Opin Cell Biol 21(2):245–255
Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, Gallinger S, Schwartz AG, Syngal S, Cote ML, Axilbund J, Schulick R, Ali SZ, Eshleman JR, Velculescu VE, Goggins M, Vogelstein B, Papadopoulos N, Hruban RH, Kinzler KW, Klein AP (2012) ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2(1):41–46
Rustgi AK (2014) Familial pancreatic cancer: genetic advances. Genes Dev 28(1):1–7
Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73:39–85
Sandhu JK, Haqqani AS, Birnboim HC (2000) Effect of dietary vitamin E on spontaneous or nitric oxide donor-induced mutations in a mouse tumor model. J Natl Cancer Inst 92(17):1429–1433
Sengupta S, Harris CC (2005) p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6(1):44–55
Srivastava N, Gochhait S, de Boer P, Bamezai RN (2009) Role of H2AX in DNA damage response and human cancers. Mutat Res 681(2–3):180–188
Thompson PA, Seyedi F, Lang NP, MacLeod SL, Wogan GN, Anderson KE, Tang YM, Coles B, Kadlubar FF (1999) Comparison of DNA adduct levels associated with exogenous and endogenous exposures in human pancreas in relation to metabolic genotype. Mutat Res 424(1–2):263–274
Traven A, Heierhorst J (2005) SQ/TQ cluster domains: concentrated ATM/ATR kinase phosphorylation site regions in DNA-damage-response proteins. BioEssays 27(4):397–407
van der Heijden MS, Yeo CJ, Hruban RH, Kern SE (2003) Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 63(10):2585–2588
Wang M, Abbruzzese JL, Friess H, Hittelman WN, Evans DB, Abbruzzese MC, Chiao P, Li D (1998) DNA adducts in human pancreatic tissues and their potential role in carcinogenesis. Cancer Res 58(1):38–41
Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326(7):455–465
Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV (2010) Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 16(5):535–543 (531 p following 143)
Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, Yu X (2009) PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 19(6):524–529
Acknowledgments
This study was supported by National Institute of Health (CA132755 and CA130899 to X.Y.), Ovarian Cancer Research Fund (292728 to M. L.), and National Natural Science Foundation of China (81272756 to Fei Li).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Michael Osterman, Deion Kathawa and Diangang Liu have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Osterman, M., Kathawa, D., Liu, D. et al. Elevated DNA damage response in pancreatic cancer. Histochem Cell Biol 142, 713–720 (2014). https://doi.org/10.1007/s00418-014-1245-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00418-014-1245-7